GENOME ANNOUNCEMENT
Klebsiella pneumoniae is an opportunistic pathogen of human mucosal surfaces resposible for community- and hospital-acquired bloodstream, respiratory, intra-abdominal, and urinary tract infections (1). Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections have been particularly associated with high mortality in infected patients (2).
K. pneumoniae KP41-2015 was isolated in 2015 from a wound swab during an outbreak of CRKP infections in patients hospitalized in two intensive care units in Brunei Darussalam (3). The strain belonged to the sequence type 231 (ST231) lineage and exhibited resistance to aminoglycosides, cephalosporins, carbapenems, fluoroquinolones, and sulfonamides but remained susceptible to polymyxins and ceftazidime-avibactam.
Genomic DNA from KP41-2015 was subjected to whole-genome sequencing using 2 × 250-bp paired-end reads on an Illumina MiSeq platform (Illumina, Inc., San Diego, CA), generating a total of 338,242 reads with an average length of 521 bp. The generated reads were trimmed using the Trimmomatic algorithm (version 0.36) (4) and their quality assessed by in-house scripts combined with SAMtools (version 1.3.1) (5), BedTools (version 2.25.0) (6), and BWA-mem (version 2) (7) algorithms. High-quality filtered reads were subsequently assembled de novo using SPAdes algorithm (version 3.7.1) (8) into 98 scaffolds, with a minimum length of 211 bp and an N50 of 316,659 bp. The sequence coverage of the de novo assemblies was approximately 190 reads per assembled base. The draft genome sequence of KP41-2015 revealed a genome size of 5,692,661 bp, with an average G+C content of 56.94%.
Provisional annotation using the ab initio gene finder algorithm Prokka (version 1.11) (9) revealed a total of 5,570 coding sequences (CDSs), including at least 82 tRNAs, 23 rRNAs (8 complete and 15 partial), and 19 ncRNAs. The determination of its antimicrobial resistome using ResFinder (10) revealed a unique complement of genes conferring resistance to aminoglycosides [aph(3′)-Ic, aacA4, and rmtf], β-lactams (blaSHV-11, blaTEM-1b, blaCTX-M-15, and blaOXA-232), fluoroquinolones (oqxA, oqxB, and qnrS1), fosfomycin (fosA), macrolides, lincosamides and streptogramin B [erm(42)], phenicols (catA1 and floR), rifampin (arr-2), and sulfonamides (sul2). PlasmidFinder (11) confirmed the presence of the A/C2, ColK(P3), FIB, and FII(K) replicon types, as we have shown earlier based on PCR-based replicon typing (Diatheva, Fano, Italy), while PHAST (12) revealed the presence of four intact, one incomplete, and two putative prophages. K. pneumoniae KP41-2015 contains genes for iron acquisition, such as kfuA and kfuC and several virulence genes including fyuA, irp1, irp2 ybtA, ybtE, ybtP, ybtQ, ybtS, ybtT, ybtU and ybtX (yersiniabactins), as well as mrkD and mrkH (type 3 fimbriae formation).
This is the first genome sequence, to our knowledge, describing the genetic factors that have contributed to the recent emergence of this multidrug-resistant clone that appears to be disseminating throughout Southeast Asia.
Accession number(s).
The draft genome sequence of K. pneumoniae KP41-2015 has been deposited at the DDBJ/EMBL/GenBank databases under the accession number MCNI00000000. The version described in this paper is the first version, MCNI01000000.
b Microbiology Laboratory Services, RIPAS Hospital, Bandar Seri Begawan, Brunei
c Department of Bacteriology and Epidemiology, CVI of Wageningen University, Lelystad, The Netherlands
d Division of Infection, Barts Healthcare NHS Trust, London, United Kingdom
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright © 2017 Abdul Momin et al. This work is licensed under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
ABSTRACT
Carbapenem-resistant Klebsiella pneumoniae infection is a rising public health threat due to limited therapeutic options. Here, we report the genome sequence of a multidrug-resistant K. pneumoniae sequence type 231 (ST231) strain associated with an outbreak of infections in an intensive care unit that carries a unique complement of resistance determinants.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer